IL6 and thrombocytosis disease: In thromboinflammatory disease, where IL-6 often co-rises with fibrin(ogen) degradation products and endothelial activation, targeting IL-6 may simultaneously mitigate coagulopathy, vascular inflammation, and secondary thrombocytosis [7].